Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05980000
Title Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)
Acronym Rambro2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.